Shopping Cart
- Remove All
Your shopping cart is currently empty
PSMA-ALB-56
😃Good
Catalog No. T39831Cas No. 2306049-48-7
PSMA-ALB-56 is a PSMA-targeting radioactive ligand with antitumor activity, composed of glutamic urea PSMA binding entities, DOTA chelating agents, and albumin binders based on 4-(p-iodophenyl)- fragment or p(tolyl)- fragment.
PSMA-ALB-56
😃Good
Catalog No. T39831Cas No. 2306049-48-7
PSMA-ALB-56 is a PSMA-targeting radioactive ligand with antitumor activity, composed of glutamic urea PSMA binding entities, DOTA chelating agents, and albumin binders based on 4-(p-iodophenyl)- fragment or p(tolyl)- fragment.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | 1.261 € | Backorder |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "PSMA-ALB-56"
Piflufolastat
DCFPYL
T312241423758-00-2In house
Piflufolastat (DCFPYL) is a PET imaging agent for prostate cancer PSMA. It is a fluorinated prostate-specific membrane antigen (PSMA) preparation. Piflufolastat can be used to prepare piflufolastat F 18 (DCFPyL F-18).
- 49 €
Size
QTY
CS-0047390
(S)-Di-tert-butyl 2-(3-((S)-6-amino-1-(tert-butoxy)-1-oxohexan-2-yl)ureido)pentanedioate
T92801025796-31-9
CS-0047390, also known as tert-Butyl-DCL, PSMA inhibitor, is a radiopaque peptide reagent.
- 31 €
Size
QTY
Deruxtecan
T150981599440-13-7
Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker used in the synthesis of DS-8201 and U3-1402.
- 132 €
Size
QTY
Mc-VC-PAB-SN38
Mc-VC-PAB-SN38
T392221801838-28-7
Mc-VC-PAB-SN38 consists of a cleavable ADC linker (Mc-VC-PAB) and SN38, which is part of an antibody-coupled reactive molecule commonly used to synthesize antibody-coupled reactive molecules (ADCs) that target sites of action.
- 183 €
Size
QTY
DUPA
N,N''-Carbonylbis[L-glutamic acid], (2S,2'S)-2,2'-Carbonylbis(Azanediyl)Dipentanedioic Acid
T19301302941-52-2
DUPA (N,N''-Carbonylbis[L-glutamic acid]) is used as the targeting moiety to actively deliver DTX for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.
- 35 €
Size
QTY
Val-Cit-PAB-MMAE
T18867644981-35-1
Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE . MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization[1].
- 47 €
Size
QTY
VCMMAE
mc-vc-PAB-MMAE
T4232646502-53-6
VCMMAE (mc-vc-PAB-MMAE) is a drug-linker conjugate for ADC with potent antitumor activity.
- 28 €
Size
QTY
Vc-MMAD
T188701401963-17-4
Vc-MMAD, a drug-linker conjugate for Antibody-Drug Conjugates (ADCs), combines the ADC linker Val-Cit (Valine-Citrulline) with the potent tubulin inhibitor MMAD. This compound leverages the targeting capability of ADCs to deliver the cytotoxic agent MMAD specifically to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects.
- 49 €
Size
QTY
Glu-urea-Lys
T89251025796-69-3
Glu-urea-Lys is a molecular scaffold that targets PSMA and can be used as a prostate cancer imaging agent to study prostate-specific membrane antigens.
- 185 €
Size
QTY
DUPA(OtBu)-OH
T111221026987-94-9
DUPA(OtBu)-OH is a precursor of DUPA, which is used as a targeting moiety to actively deliver Docetaxel (DTX) for treating Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer, with PSMA showing high affinity for DUPA (Ki = 8 nM).
- 27 €
Size
QTY
SMCC-DM1
DM1-SMCC
T168991228105-51-8
SMCC-DM1 is a drug-coupler coupler consisting of a potent microtubule disrupter, DM1, and a coupler, SMCC, for the preparation of antibody-drug couplers.
- 92 €
Size
QTY
Fmoc-Val-Cit-PAB-MMAE
T179831350456-56-2
Fmoc-Val-Cit-PAB-MMAE is consisted of the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.
- 35 €
Size
QTY
Select Batch
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | PSMA-ALB-56 is a PSMA-targeting radioactive ligand with antitumor activity, composed of glutamic urea PSMA binding entities, DOTA chelating agents, and albumin binders based on 4-(p-iodophenyl)- fragment or p(tolyl)- fragment. |
| In vivo | PSMA-ALB-56 demonstrates rapid accumulation in tumor tissues and enhanced clearance from the bloodstream and non-target tissues, leading to superior tumor-to-background contrast within just 4 hours post-injection. Additionally, PSMA-ALB-56 is associated with an increase in median survival in mice [1]. |
| Molecular Weight | 1330.52 |
| Formula | C66H95N11O18 |
| Cas No. | 2306049-48-7 |
| Smiles | Cc1ccc(CCCC(=O)NCCCC[C@H](NC(=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)C(=O)NC[C@H]2CC[C@@H](CC2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)NCCCC[C@H](NC(=O)N[C@@H](CCC(O)=O)C(O)=O)C(O)=O)cc1 |
| Relative Density. | 1.276 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy PSMA-ALB-56 | purchase PSMA-ALB-56 | PSMA-ALB-56 cost | order PSMA-ALB-56 | PSMA-ALB-56 chemical structure | PSMA-ALB-56 in vivo | PSMA-ALB-56 formula | PSMA-ALB-56 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.